drugset / Trial / NCT04658927
Dextenza With ILUX for Treatment of MGD
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the benefit of treatment with a physician administered intracanalicular dexamethasone insert in evaporative dry eye disease (DED) patients with meibomian gland disfunction (MGD) and underlying inflammation undergoing iLUX MGD Treatment System.
Timeline
- Start
- 2021-01-04
- Primary completion
- 2021-01-11
- Completion
- 2021-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexamethasone | Small molecule | 0.4 mg | Other |
| Comparator | Prednisone | Other / unclassified | 1 % | Topical |